-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Enovis (NYSE:ENOV) & Coloplast A/S (OTCMKTS:CLPBY) Head to Head Contrast
Enovis (NYSE:ENOV) & Coloplast A/S (OTCMKTS:CLPBY) Head to Head Contrast
Enovis (NYSE:ENOV – Get Rating) and Coloplast A/S (OTCMKTS:CLPBY – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Earnings and Valuation
This table compares Enovis and Coloplast A/S's gross revenue, earnings per share and valuation.
Get Enovis alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Enovis | $3.85 billion | 0.88 | $71.66 million | $0.48 | 131.19 |
Coloplast A/S | $2.76 billion | 9.37 | $585.21 million | $0.28 | 42.79 |
Coloplast A/S has lower revenue, but higher earnings than Enovis. Coloplast A/S is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Enovis and Coloplast A/S's net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
Enovis | 0.94% | 4.46% | 2.78% |
Coloplast A/S | 21.62% | 69.30% | 33.77% |
Insider & Institutional Ownership
96.7% of Enovis shares are held by institutional investors. Comparatively, 0.1% of Coloplast A/S shares are held by institutional investors. 8.3% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Enovis has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Enovis and Coloplast A/S, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Enovis | 0 | 2 | 7 | 0 | 2.78 |
Coloplast A/S | 1 | 2 | 2 | 0 | 2.20 |
Enovis presently has a consensus target price of $63.50, suggesting a potential upside of 0.84%. Given Enovis' stronger consensus rating and higher probable upside, research analysts clearly believe Enovis is more favorable than Coloplast A/S.
Summary
Enovis beats Coloplast A/S on 9 of the 14 factors compared between the two stocks.
About Enovis
(Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
About Coloplast A/S
(Get Rating)
Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
Enovis (NYSE:ENOV – Get Rating) and Coloplast A/S (OTCMKTS:CLPBY – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Enovis(NYSE:ENOV-GET Rating)和Colopast A/S(OTCMKTS:CLPBY-GET Rating)都是医疗公司,但哪一家业务更好?我们将根据这两家公司的机构持股、股息、盈利能力、收益、分析师建议、风险和估值等方面的实力进行比较。
Earnings and Valuation
收益和估值
This table compares Enovis and Coloplast A/S's gross revenue, earnings per share and valuation.
此表比较了Enovis和Colopast A/S的毛收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Enovis | $3.85 billion | 0.88 | $71.66 million | $0.48 | 131.19 |
Coloplast A/S | $2.76 billion | 9.37 | $585.21 million | $0.28 | 42.79 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
伊诺维斯 | 38.5亿美元 | 0.88 | 7166万美元 | $0.48 | 131.19 |
叶绿体A/S | 27.6亿美元 | 9.37 | 5.8521亿美元 | $0.28 | 42.79 |
Coloplast A/S has lower revenue, but higher earnings than Enovis. Coloplast A/S is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.
Colplast A/S的收入低于Enovis,但收益高于Enovis。Colopast A/S的市盈率低于Enovis,表明它目前是两只股票中更负担得起的一只。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
Enovis | 0.94% | 4.46% | 2.78% |
Coloplast A/S | 21.62% | 69.30% | 33.77% |
净利润率 | 股本回报率 | 资产回报率 | |
伊诺维斯 | 0.94% | 4.46% | 2.78% |
叶绿体A/S | 21.62% | 69.30% | 33.77% |
Insider & Institutional Ownership
内部人与机构所有权
96.7% of Enovis shares are held by institutional investors. Comparatively, 0.1% of Coloplast A/S shares are held by institutional investors. 8.3% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Enovis 96.7%的股份由机构投资者持有。相比之下,科莱普斯特A/S公司0.1%的股份由机构投资者持有。Enovis 8.3%的股份由公司内部人士持有。强大的机构持股表明,对冲基金、捐赠基金和大型基金管理公司相信,一家公司有望实现长期增长。
Risk & Volatility
风险与波动性
Enovis has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Enovis的Beta值为2.04,表明其股价的波动性比标准普尔500指数高104%。相比之下,Colopast A/S的贝塔系数为0.28,表明其股价的波动性比标准普尔500指数低72%。
Analyst Recommendations
分析师建议
This is a summary of current recommendations and price targets for Enovis and Coloplast A/S, as provided by MarketBeat.com.
这是由MarketBeat.com提供的对Enovis和Colopast A/S的当前建议和目标价的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Enovis | 0 | 2 | 7 | 0 | 2.78 |
Coloplast A/S | 1 | 2 | 2 | 0 | 2.20 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
伊诺维斯 | 0 | 2 | 7 | 0 | 2.78 |
叶绿体A/S | 1 | 2 | 2 | 0 | 2.20 |
Enovis presently has a consensus target price of $63.50, suggesting a potential upside of 0.84%. Given Enovis' stronger consensus rating and higher probable upside, research analysts clearly believe Enovis is more favorable than Coloplast A/S.
Enovis目前的共识目标价为63.50美元,暗示潜在上行0.84%。鉴于Enovis的更高共识评级和更高的可能上行空间,研究分析师显然认为Enovis比Colplast A/S更有利。
Summary
摘要
Enovis beats Coloplast A/S on 9 of the 14 factors compared between the two stocks.
在两只股票之间进行比较的14个因素中,Enovis有9个胜过Colplast A/S。
About Enovis
关于Enovis
(Get Rating)
(获取评级)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Enovis公司是一家全球性的医疗技术公司。该公司开发、制造和分销医疗器械产品,供整形外科专家、外科医生、初级保健医生、疼痛管理专家、物理治疗师、足科医生、脊椎按摩师、运动训练师和其他医疗保健专业人员使用,以治疗因退行性疾病、畸形、创伤事件和运动相关伤害而导致的肌肉骨骼疾病患者。它提供坚硬和柔软的矫形支撑、冷热治疗产品、骨生长刺激器、血管治疗系统和加压服装、治疗鞋和衬垫、用于疼痛管理的电刺激器和物理治疗产品;以及一套用于髋关节、膝部、肩部、肘部、足部、脚踝和手指的重建关节产品。Enovis Corporation通过医疗保健专业人员、消费者零售店和药店等独立分销商销售其产品,并直接以DJO品牌销售。该公司的前身是科尔法克斯公司。Enovis公司总部设在特拉华州威尔明顿。
About Coloplast A/S
关于Colplast A/S
(Get Rating)
(获取评级)
Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
Colplast A/S公司开发、制造和营销医疗产品。它通过以下部分开展工作:慢性护理、介入泌尿外科和创伤与皮肤护理。慢性护理部门包括造口护理产品和失禁护理产品的销售。介入泌尿外科部门涵盖了泌尿外科产品的销售,包括一次性产品。伤口和皮肤护理部门包括伤口和皮肤护理产品的销售。该公司由Aage Louis-Hansen和Johanne Louise-Hansen于1954年创立,总部设在丹麦的Humlebaek。
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Enovis Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Enovis和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧